

WS 3: DEFINING A CORE OUTCOME SET FOR PHARMACEUTICAL CARE PROJECTS



10th PCNE Working conference, Bled 2017

Facilitators:

Prof. Veerle Foulon, KU Leuven, Departement
Farmaceutische en Farmacologische
Wetenschappen

Dr. Anna Millar, School of Pharmacy, Queen's
University Belfast

Overall aim of workshop

2

To produce a protocol for the development of a core outcome set for use in a particular area of pharmaceutical care research



What has been done?

3

- In-depth discussion on the methodology that can / should be used to develop a COS
- Brainstorm on different themes (related to Pharmaceutical Care) for which a COS might be needed and could be developed
- Drafting a preliminary protocol for three COSs
- Consensus-exercise on which outcomes to select from a literature search for the selected COSs

Themes selected

4

- COS for studies aiming to investigate the impact of pharmacists interventions in the management of anti-coagulant therapy (1)
- COS for studies investigating the impact of patient counseling on prescription drugs at the pharmacy counter (2)
- COS for studies investigating interventions aiming at continuity of medication management at hospital discharge (3)

Outcomes selected (1)

5

- Time under therapeutic range
- Thrombo-embolic events
- Major bleeding
- Total bleeding
- ED visits (due to the use of Anti-Co)
- Hospitalization due to the use of Anti-Co
- All cause mortality

Outcomes selected (2a)

6

- Drug handling problems
- Adherence
- Drug therapy problems
- (Patient) Security
- (Patient) Confidence
- Patient knowledge
- (Patient) Satisfaction

Outcomes selected (2b)

7

- Achievement of (therapeutic) goal
- Therapeutic duplication
- Inappropriate prescribing
- Disease exacerbation
- Costs of drugs
- Extra visits to GPs
- Hospital admission
- Emergency visits

Outcomes selected (3)

8

- Health related quality of life
- Medication-related hospital (re-)admission
- Potentially Inappropriate Medication
- Emergency department visits
- Medication profile appropriateness
- Adverse Drug Events
- Adherence
- GP post-discharge visits

How to continue?

9

- Theme 1: take further within PCNE - iPACT?
Funding opportunities?
- Contact person: Isabelle Waltering
(i.waltering@akwl.de)
- Theme 2: take further, if enough people with
interest in concrete projects on that theme
- Theme 3: take further within PCNE – many
projects ongoing on that theme
Contact person: Bjarke Abrahamsen
(bja@pharmakon.dk)

Other ideas

10

- ❑ Develop different COS for the different levels of Medication Review (so far: only COS for clinical MR)
- ❑ Search for funding possibilities
 - ❑ COST action of the European Union? Would offer possibilities to meet

10th PCNE Working conference, Bled

11



Facilitators:

Prof. Veerle Foulon, KU Leuven, Departement Farmaceutische en Farmacologische Wetenschappen

Email: veerle.foulon@kuleuven.be

Dr. Anna Millar, School of Pharmacy, Queen's University Belfast

Email: anna.millar@qub.ac.uk